Literature DB >> 29293366

Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.

Ozan Cem Guler1, Nese Torun2, Berna Akkus Yildirim3, Cem Onal3.   

Abstract

OBJECTIVE: To evaluate the prognostic significance of metabolic parameters derived from fludeoxyglucose (FDG) positron emission tomography (PET)/CT, in cervical cancer patients treated with concurrent chemoradiotherapy.
METHODS: We retrospectively reviewed medical records from 129 biopsy-proven non-metastatic cervical cancer patients treated with external radiotherapy and intracavitary brachytherapy at our department. Correlation between metabolic parameters and tumour characteristics was evaluated. Prognostic factors for survival, local control and distant metastasis were analysed.
RESULTS: The median follow up for all patients and surviving patients was 30.0 months (range, 3.7-94.7 months) and 50.5 months (range, 14.5-94.7 months), respectively. The 2- and 5-year overall survival (OS) and disease-free survival (DFS) rates were 68 42, 54 and 38%, respectively. The maximum standardized uptake value (SUVmax), SUVmean, metabolic tumour volume (MTV) and total lesion glycolysis were significantly higher in patients with larger tumours (>4 cm) and partial regression or progressive disease after definitive treatment compared to patients with smaller tumour (≤4 cm) and post-treatment complete response. On univariate analysis, stage, lymph node metastasis, tumour size >4 cm, SUVmax, MTV, SUVmean and total lesion glycolysis were prognostic factors for OS and DFS. On multivariate analysis, only larger tumour and presence of lymph node metastasis were significant prognostic factors for both OS and DFS. Additionally, extensive stage was a significant prognosticator for DFS.
CONCLUSION: Although, metabolic parameters derived from FDG-PET/CT had a prognostic significance in univariate analysis, the significance was lost in multivariate analysis where tumour stage, size and lymph node status were the only independent parameters. Advances in knowledge: The clinical benefit of using FDG-PET/CT metabolic parameters to evaluate the high-risk patients among cervical cancer patients and to eventually change patient management still needs further clarification.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29293366      PMCID: PMC5965999          DOI: 10.1259/bjr.20170552

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  36 in total

1.  18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.

Authors:  Cinzia Crivellaro; Mauro Signorelli; Luca Guerra; Elena De Ponti; Alessandro Buda; Carlotta Dolci; Cecilia Pirovano; Sergio Todde; Robert Fruscio; Cristina Messa
Journal:  Gynecol Oncol       Date:  2012-07-06       Impact factor: 5.482

2.  Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.

Authors:  Jin Hwa Hong; Un Suk Jung; Kyung Jin Min; Jae Kwan Lee; Sungeun Kim; Jae Seon Eo
Journal:  Nucl Med Commun       Date:  2016-08       Impact factor: 1.690

3.  Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.

Authors:  Julie K Schwarz; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  JAMA       Date:  2007-11-21       Impact factor: 56.272

4.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

5.  Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.

Authors:  Masahiro Okada; Taro Shimono; Yoshihiro Komeya; Rina Ando; Yuki Kagawa; Takashi Katsube; Masatomo Kuwabara; Yukinobu Yagyu; Seishi Kumano; Izumi Imaoka; Norio Tsuchiya; Ryuichiro Ashikaga; Makoto Hosono; Takamichi Murakami
Journal:  Ann Nucl Med       Date:  2009-04-02       Impact factor: 2.668

6.  Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.

Authors:  Terence Z Wong; Ellen L Jones; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2004 Jan-Feb       Impact factor: 3.488

7.  Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours.

Authors:  Won Jun Kang; June-Key Chung; Young So; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 8.  The prognostic value of PET and PET/CT in cervical cancer.

Authors:  Perry W Grigsby
Journal:  Cancer Imaging       Date:  2008-07-24       Impact factor: 3.909

9.  [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.

Authors:  Fernanda G Herrera; Thomas Breuneval; John O Prior; Jean Bourhis; Mahmut Ozsahin
Journal:  Radiat Oncol       Date:  2016-03-16       Impact factor: 3.481

10.  Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.

Authors:  Gun Oh Chong; Shin Young Jeong; Shin-Hyung Park; Yoon Hee Lee; Sang-Woo Lee; Dae Gy Hong; Jae-Chul Kim; Yoon Soon Lee; Young Lae Cho
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more
  5 in total

1.  Receptor for activated C kinase 1 promotes cervical cancer lymph node metastasis via the glycolysis‑dependent AKT/mTOR signaling.

Authors:  Lixiu Xu; Jinqiu Li; Mikrban Tursun; Yan Hai; Hatila Tursun; Batur Mamtimin; Ayshamgul Hasim
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

2.  Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational 18F-FDG PET/CT study.

Authors:  Siyao Du; Hongzan Sun; Si Gao; Jun Xin; Zaiming Lu
Journal:  Quant Imaging Med Surg       Date:  2019-03

3.  A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.

Authors:  Chunsheng Wang; Kewei Zhao; Shanliang Hu; Yong Huang; Li Ma; Yipeng Song; Minghuan Li
Journal:  BMC Cancer       Date:  2020-06-10       Impact factor: 4.430

4.  The Role of the Metabolic Parameters of 18F-FDG PET/CT in Patients With Locally Advanced Cervical Cancer.

Authors:  Dunhuang Wang; Xiaoliang Liu; Weiping Wang; Li Huo; Qingqing Pan; Xue Ren; Fuquan Zhang; Ke Hu
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244

5.  Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.

Authors:  Alejandra Martinez; Elodie Chantalat; Martina Aida Angeles; Gwénaël Ferron; Anne Ducassou; Manon Daix; Justine Attal; Sarah Bétrian; Amélie Lusque; Erwan Gabiache
Journal:  BMC Cancer       Date:  2022-07-23       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.